Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP726636.RAsRcB644C7UKZkAGRBsCxgEuQ9J7InbV3YJJIDy0wVMI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP726636.RAsRcB644C7UKZkAGRBsCxgEuQ9J7InbV3YJJIDy0wVMI130_assertion type Assertion NP726636.RAsRcB644C7UKZkAGRBsCxgEuQ9J7InbV3YJJIDy0wVMI130_head.
- NP726636.RAsRcB644C7UKZkAGRBsCxgEuQ9J7InbV3YJJIDy0wVMI130_assertion description "[TMPRSS2-ERG, TMPRSS2-ETV1, and SLC45A3-ERG rearrangements account for roughly 90% of ETS fusion prostate cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP726636.RAsRcB644C7UKZkAGRBsCxgEuQ9J7InbV3YJJIDy0wVMI130_provenance.
- NP726636.RAsRcB644C7UKZkAGRBsCxgEuQ9J7InbV3YJJIDy0wVMI130_assertion evidence source_evidence_literature NP726636.RAsRcB644C7UKZkAGRBsCxgEuQ9J7InbV3YJJIDy0wVMI130_provenance.
- NP726636.RAsRcB644C7UKZkAGRBsCxgEuQ9J7InbV3YJJIDy0wVMI130_assertion SIO_000772 19293179 NP726636.RAsRcB644C7UKZkAGRBsCxgEuQ9J7InbV3YJJIDy0wVMI130_provenance.
- NP726636.RAsRcB644C7UKZkAGRBsCxgEuQ9J7InbV3YJJIDy0wVMI130_assertion wasDerivedFrom befree-2016 NP726636.RAsRcB644C7UKZkAGRBsCxgEuQ9J7InbV3YJJIDy0wVMI130_provenance.
- NP726636.RAsRcB644C7UKZkAGRBsCxgEuQ9J7InbV3YJJIDy0wVMI130_assertion wasGeneratedBy ECO_0000203 NP726636.RAsRcB644C7UKZkAGRBsCxgEuQ9J7InbV3YJJIDy0wVMI130_provenance.